Val J. Lowe

Val J. Lowe's AcademicInfluence.com Rankings

Val J. Lowe

Philosophy

#6329

World Rank

#9350

Historical Rank

Logic

#3507

World Rank

#4682

Historical Rank

philosophy Degrees

Val J. Lowe

Biology

#8591

World Rank

#11691

Historical Rank

Neuroscience

#1194

World Rank

#1238

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Val J. Lowe's Degrees

Doctorate Medicine Stanford University

Why Is Val J. Lowe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Val J. Lowe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009) (1017)
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. (2008) (876)
Recommendations on the Use of 18F-FDG PET in Oncology (2008) (766)
Prospective investigation of positron emission tomography in lung nodules. (1998) (565)
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease (2012) (560)
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. (1993) (523)
Defining imaging biomarker cut points for brain aging and Alzheimer's disease (2017) (470)
An autoradiographic evaluation of AV-1451 Tau PET in dementia (2016) (383)
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. (2000) (380)
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72 (2012) (341)
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography (2018) (314)
Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech (2012) (306)
Brain β-amyloid load approaches a plateau (2013) (300)
Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study (2014) (300)
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. (2013) (283)
Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. (2015) (276)
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. (1994) (273)
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 (2018) (271)
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum (2015) (270)
Longitudinal tau PET in ageing and Alzheimer’s disease (2018) (259)
Remission of disseminated cancer after systemic oncolytic virotherapy. (2014) (249)
11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (240)
Surveillance for recurrent head and neck cancer using positron emission tomography. (2000) (239)
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. (1995) (234)
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease (2012) (227)
Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly (2015) (219)
Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in Mice (2016) (218)
Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. (1994) (198)
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). (1995) (197)
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity (2013) (188)
Comparison of 18F-FDG and PiB PET in Cognitive Impairment (2009) (188)
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. (2018) (186)
Multimodality imaging characteristics of dementia with Lewy bodies (2012) (180)
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. (2020) (174)
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly (2013) (173)
Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. (1995) (172)
Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings (2015) (166)
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. (2019) (165)
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. (2013) (158)
Effect of lifestyle activities on alzheimer disease biomarkers and cognition (2012) (158)
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. (2016) (156)
Autoimmune dementia: clinical course and predictors of immunotherapy response. (2010) (155)
Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study (2017) (153)
Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework (2019) (152)
Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer (2005) (151)
Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. (2006) (146)
APOE modifies the association between Aβ load and cognition in cognitively normal older adults (2012) (146)
Indicators of amyloid burden in a population-based study of cognitively normal elderly (2012) (144)
A Comparison of the Diagnostic Accuracy of 18F-FDG PET and CT in the Characterization of Solitary Pulmonary Nodules (2008) (140)
Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. (1995) (140)
Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures (2015) (139)
AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies (2016) (137)
Clinical Significance of Diffusely Increased 18F-FDG Uptake in the Thyroid Gland (2007) (134)
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum (2017) (133)
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration (2014) (131)
Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. (2018) (130)
Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation (2014) (130)
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample (2017) (129)
Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech (2015) (126)
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. (2012) (126)
Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. (1996) (125)
Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA (2013) (122)
Association of Excessive Daytime Sleepiness With Longitudinal &bgr;-Amyloid Accumulation in Elderly Persons Without Dementia (2018) (121)
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study (2016) (118)
Pulmonary abnormalities and PET data analysis: a retrospective study. (1997) (117)
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. (2007) (116)
[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy (2017) (116)
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration (2016) (114)
The role of LAT1 in 18F-DOPA uptake in malignant gliomas (2012) (114)
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET–CT (2007) (113)
NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. (2006) (111)
The evolution of primary progressive apraxia of speech. (2014) (106)
Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express the Sodium Iodide Symporter in Patients with Recurrent or Refractory Multiple Myeloma (2017) (105)
Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART) (2017) (105)
Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. (2013) (103)
FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type (2013) (102)
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes (2019) (102)
Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia (2012) (102)
Dementia with Lewy bodies (2014) (102)
Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals (2017) (102)
18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons (2014) (100)
Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting (2018) (98)
NEMA NU 2-2007 performance measurements of the Siemens Inveon™ preclinical small animal PET system (2009) (95)
White matter hyperintensities: relationship to amyloid and tau burden. (2019) (93)
Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. (2014) (89)
Tau-positron emission tomography correlates with neuropathology findings (2019) (88)
Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition (2016) (85)
Positron emission tomography in lung cancer. (1998) (84)
Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. (2005) (83)
Prosodic and phonetic subtypes of primary progressive apraxia of speech (2018) (82)
18F-FDG PET of patients with Hürthle cell carcinoma. (2003) (81)
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition (2016) (80)
18F-FDG labelling of human leukocytes (2000) (80)
Current role of positron emission tomography in thoracic oncology (1998) (76)
Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. (2009) (75)
The cost‐effectiveness of fluorodeoxyglucose 18‐F positron emission tomography in the N0 neck (2001) (73)
Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. (2013) (72)
18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies (2017) (71)
Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies (2012) (71)
Effect of intellectual enrichment on AD biomarker trajectories (2016) (70)
Structural and functional imaging in parkinsonian syndromes. (2014) (70)
Association of hypometabolism and amyloid levels in aging, normal subjects (2014) (68)
Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study (2013) (67)
Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease (2018) (66)
Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. (2012) (65)
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. (2021) (64)
Distinct cytokine profiles in human brains resilient to Alzheimer's pathology (2019) (64)
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. (2008) (63)
Progranulin-associated PiB-negative logopenic primary progressive aphasia (2014) (63)
Biodistribution and dosimetry of [18F]fluorodeoxyglucose labelled leukocytes in normal human subjects (2002) (62)
Entorhinal cortex tau, amyloid-&bgr;, cortical thickness and memory performance in non-demented subjects (2019) (62)
Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults (2011) (62)
Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes (2020) (61)
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. (2016) (61)
In Vivo Quantitation of Intratumoral Radioisotope Uptake Using Micro-Single Photon Emission Computed Tomography/Computed Tomography (2006) (61)
Local recurrence of rectal cancer:evaluation with F-18 fluorodeoxyglucose PET imaging (1997) (61)
The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. (2008) (60)
Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. (2005) (59)
Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. (2014) (59)
The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies (2019) (59)
FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis (2018) (58)
Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. (2009) (58)
White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. (2014) (58)
Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. (2019) (57)
Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor (2005) (57)
Atrial fibrillation, cognitive impairment, and neuroimaging (2016) (56)
[18F]AV‐1451 tau‐PET and primary progressive aphasia (2018) (56)
In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms (2018) (56)
Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE (2017) (56)
MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies (2013) (56)
[18F]AV‐1451 clustering of entorhinal and cortical uptake in Alzheimer's disease (2018) (55)
FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants (2014) (54)
Clinical, FDG and amyloid PET imaging in posterior cortical atrophy (2015) (54)
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research (2021) (54)
Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. (2008) (53)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. (2014) (51)
Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI (2013) (51)
Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia (2015) (50)
Predicting future rates of tau accumulation on PET (2020) (50)
Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. (2017) (50)
Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults (2019) (49)
Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease (2019) (49)
Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment (2010) (48)
Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. (2008) (48)
Visual Assessment Versus Quantitative Three-Dimensional Stereotactic Surface Projection Fluorodeoxyglucose Positron Emission Tomography for Detection of Mild Cognitive Impairment and Alzheimer Disease (2012) (48)
Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial (2018) (48)
Contemporary Mapping of Post‐Prostatectomy Prostate Cancer Relapse with 11C‐Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging (2017) (47)
A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain (2011) (47)
DEMENTIA WITH LEWY BODIES (2004) (47)
Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?☆ (2013) (47)
Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods (2018) (47)
Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging (2019) (46)
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients (2007) (45)
Positron emission tomography and sentinel lymph node dissection in breast cancer. (2002) (45)
Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study (2014) (45)
Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration (2018) (45)
Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals (2017) (45)
Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort (2016) (44)
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. (2008) (44)
Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status (2017) (43)
Cardiac phantom evaluation of simultaneously acquired dual-isotope rest thallium-201/stress technetium-99m SPECT images. (1993) (43)
Performance of plasma phosphorylated tau 181 and 217 in the community (2022) (43)
A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR (2018) (42)
Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease (2018) (41)
Clinical 18F-FDG oncology patient preparation techniques. (2003) (41)
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. (2013) (41)
Positron emission tomography for basal cell carcinoma of the head and neck. (2003) (41)
18F-FDG PET and PET/CT in Burkitt's lymphoma. (2010) (41)
Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. (2018) (40)
Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging (2017) (40)
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. (2020) (40)
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain (2017) (39)
Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. (2020) (39)
Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. (1999) (39)
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. (2008) (39)
Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging (2018) (38)
Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech (2018) (38)
Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. (2006) (37)
β-Amyloid PET and neuropathology in dementia with Lewy bodies (2019) (37)
Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease (2015) (37)
The role of positron emission tomography in the management of non-small cell lung cancer. (2009) (37)
Increased Brain Glucose Uptake After 12 Weeks of Aerobic High-Intensity Interval Training in Young and Older Adults (2018) (36)
Using fluorodeoxythymidine to monitor anti‐EGFR inhibitor therapy in squamous cell carcinoma xenografts (2008) (36)
Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia (2018) (36)
¹¹C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. (2016) (36)
Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis (2019) (35)
The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma (2010) (35)
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease (2019) (35)
Update in PET imaging of nonsmall cell lung cancer. (2004) (35)
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis (2018) (35)
Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants (2019) (35)
Associations of quantitative susceptibility mapping with Alzheimer’s disease clinical and imaging markers (2020) (35)
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies (2020) (34)
The pimple sign of progressive supranuclear palsy syndrome. (2014) (34)
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging (2015) (33)
Prevalence and Natural History of Superficial Siderosis: A Population-Based Study (2017) (33)
Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. (2016) (33)
Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults (2019) (32)
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies (2016) (32)
Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging (2019) (32)
Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. (2011) (32)
FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging (2016) (32)
Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. (2017) (31)
Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography (2013) (30)
LRRK2 variation and dementia with Lewy bodies. (2016) (29)
18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus (2018) (29)
Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. (2020) (29)
APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia (2014) (29)
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy (2018) (28)
A robust biomarker of large-scale network failure in Alzheimer's disease (2017) (28)
The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease (2019) (28)
BBBomics-Human Blood Brain Barrier Transcriptomics Hub (2016) (28)
Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain (2014) (28)
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging (2014) (28)
HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer (2015) (27)
Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. (2019) (27)
Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals (2017) (26)
A Comparison of the Diagnostic Accuracy of 18 F-FDG PET and CT in the Characterization of Solitary Pulmonary Nodules (2008) (26)
Joint associations of β-amyloidosis and cortical thickness with cognition (2018) (26)
Biopsy validation of 18 F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation : results of a prospective pilot study (2013) (26)
APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) (26)
Normal variants and pitfalls in whole-body PET imaging with 18F FDG (2006) (26)
Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET (2018) (26)
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma (2017) (26)
Predicting Progression to Mild Cognitive Impairment (2019) (26)
White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition (2018) (26)
Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. (2015) (26)
Antemortem amyloid imaging and β -amyloid pathology in a case with dementia with Lewy Bodies (2012) (25)
A hand-held beta imaging probe for FDG (2013) (25)
Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia (2019) (25)
Multimorbidity and neuroimaging biomarkers among cognitively normal persons (2016) (25)
Cerebral microbleeds (2018) (25)
Triple-technique (MR imaging, single-photon emission CT, and CT) coregistration for image-guided surgical evaluation of patients with intractable epilepsy. (1999) (25)
Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia (2013) (25)
Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. (2018) (24)
The Utility of Positron Emission Tomography in the Evaluation of Autoimmune Hearing Loss (2003) (24)
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia (2018) (24)
Contributions of imprecision in PET‐MRI rigid registration to imprecision in amyloid PET SUVR measurements (2017) (24)
Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia (2016) (24)
Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. (2018) (24)
Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum (2016) (23)
Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB‐PET Study (2017) (23)
Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature. (2013) (22)
Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration (2020) (22)
Assessment of Lymphoma Therapy Using (18)F-FDG PET. (2002) (22)
Preparation and Preliminary Evaluation of 63Zn-Zinc Citrate as a Novel PET Imaging Biomarker for Zinc (2014) (22)
The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging (2018) (22)
Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study (2016) (22)
Cerebral microbleed incidence, relationship to amyloid burden (2019) (21)
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. (2016) (21)
Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction from 18F-DOPA-PET Imaging. (2020) (21)
18F-FDG PET Scanning in Pulmonary Amyloidosis (2014) (21)
[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation (2018) (21)
Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. (2018) (20)
RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies (2016) (20)
First PET Imaging Studies With 63Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease (2016) (20)
Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging (2020) (20)
Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants (2018) (20)
1H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults (2017) (19)
Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72. (2012) (19)
TREM2 p.R47H substitution is not associated with dementia with Lewy bodies (2016) (19)
Serial Evaluation of Increased Chest Wall F-18 Fluorodeoxyglucose (FDG) Uptake Following Radiation Therapy in Patients With Bronchogenic Carcinoma. (1998) (19)
Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele (2019) (19)
Correlation of Fine Needle Aspiration Biopsy and Fluoride-18 Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Locally Recurrent and Metastatic Head and Neck Neoplasia (1998) (19)
A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech (2021) (19)
Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas (2018) (19)
18F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy (2019) (18)
Early detection of prostate cancer relapse by biochemistry and diagnostic imaging. (2015) (18)
Overexpression of MPS antigens by squamous cell carcinomas of the head and neck: immunohistochemical and serological correlation with FDG positron emission tomography. (1999) (18)
Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. (2015) (18)
Investigation of white matter PiB uptake as a marker of white matter integrity (2019) (18)
Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects (2017) (18)
Regional β‐amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia (2016) (18)
Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. (2018) (18)
Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly (2020) (17)
F-18 FDG PET scan after radiotherapy for early-stage larynx cancer. (1998) (17)
NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages (2021) (17)
Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. (2015) (17)
Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis (2016) (17)
Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies (2011) (17)
Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers (2017) (16)
The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. (2018) (16)
Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy (2020) (16)
Multiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings (2016) (16)
PREDICTORS OF REGIONAL TAU-PET UPTAKE: MAYO CLINIC STUDY OF AGING (2016) (16)
11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities (2019) (16)
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis (2020) (16)
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. (2019) (16)
Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study (2015) (16)
Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC) (2021) (16)
Microbleeds in the logopenic variant of primary progressive aphasia (2014) (15)
18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study (2019) (15)
Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin (2012) (15)
Initial results of a phase II trial of 18F-DOPA PET-guided dose-escalated radiotherapy for glioblastoma. (2021) (15)
Metallopanstimulin as a marker for head and neck cancer (2004) (15)
Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study. (2021) (15)
Multimodal neuroimaging relationships in progressive supranuclear palsy. (2019) (15)
Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults (2020) (15)
The GGGGCC Repeat Expansion in C9ORF72 in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome (2014) (15)
Operational Characteristics Of 11 C-Choline PET/CT For Prostate Cancer Patients With Biochemical Recurrence Following Initial Treatment. (2012) (14)
FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD (2021) (14)
Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks (2021) (14)
P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status (2021) (14)
Identification of Recurrence Sites Following Post‐Prostatectomy Treatment for Prostate Cancer Using 11C‐Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging (2018) (14)
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study (2018) (14)
Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. (2020) (14)
Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies (2021) (14)
Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation (2021) (13)
Deep learning-based brain age prediction in normal aging and dementia (2021) (13)
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes (2021) (13)
Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. (2020) (13)
Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype (2020) (13)
Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma with radiation (1994) (13)
MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous (2020) (13)
Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech (2018) (13)
Pretreatment with Diphenoxylate Hydrochloride/Atropine Sulfate (Lomotil) does not Decrease Physiologic Bowel FDG Activity on PET/CT Scans of the Abdomen and Pelvis (2008) (13)
Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia (2014) (13)
Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia (2018) (12)
NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. (2014) (12)
Initial Results of a Phase II Trial of 18f-Dopa Pet-guided Dose-escalated Radiotherapy for Glioblastoma (2020) (12)
The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. (2020) (12)
Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. (2020) (12)
Perceived Misinterpretation Rates in Oncologic 18F-FDG PET/CT Studies: A Survey of Referring Physicians (2014) (12)
The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. (2009) (12)
Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology (2021) (11)
Oncologic 18F-FDG PET/CT: Referring Physicians’ Point of View (2012) (11)
Performance measurements of a whole body PET/CT system with time-of-flight capability (2009) (11)
11 C PiB and Structural MRI Provide Complementary Information in Imaging of AD and Amnestic MCI (2009) (11)
Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders (2020) (10)
PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. (2009) (10)
Clinicopathological and 123I‐FP‐CIT SPECT correlations in patients with dementia (2018) (10)
UTILITY OF PMOD IMAGE QUANTIFICATION SOFTWARE FOR PROCESSING [11C]PIB AND [18F]FLUTEMETAMOL IMAGES FOR SUVR QUANTITATION ON THE CENTILOID SCALE (2016) (10)
A computational model of neurodegeneration in Alzheimer’s disease (2022) (10)
Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia (2019) (10)
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance) (2018) (10)
PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (9)
18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies (2020) (9)
The neural basis of naming impairments in Alzheimer's disease revealed through positron emission tomography. (1999) (9)
Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. (2020) (9)
The flip-flop fungus sign: an FDG PET/CT sign of benignity. (2017) (9)
Expression of p53 protein in advanced head and neck squamous cell carcinoma before and after chemotherapy. (1997) (9)
Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech (2016) (9)
OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma (2017) (8)
A novel imaging beta probe for radio-guided surgery (2008) (8)
Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes (2020) (8)
Variants in PPP2R2B and IGF2BP3 are associated with higher tau deposition (2020) (8)
Distinct Uptake Kinetics of Alzheimer Disease Amyloid-β 40 and 42 at the Blood-Brain Barrier Endothelium (2020) (8)
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer (2021) (8)
False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1. (2011) (8)
Cholangiocarcinoma Metastatic to the Neck: First Report of a Case (2002) (8)
High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-β Distribution between Brain and Plasma (2020) (7)
Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease (2021) (7)
Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. (2022) (7)
Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population (2021) (7)
The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia (2019) (7)
Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology (2022) (7)
Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values (2018) (7)
Esophageal cancer and head and neck cancer. (2002) (6)
Brain Metabolic Changes with Longitudinal Transcutaneous Afferent Patterned Stimulation in Essential Tremor Subjects (2020) (6)
White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline (2021) (6)
Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech (2020) (6)
Cerebrospinal fluid dynamics disorders (2019) (6)
Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET (2021) (6)
Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. (2020) (6)
Relationship Between 18F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies (2021) (5)
Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas (2018) (5)
Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors (2017) (5)
Characterization of a Family With c 9 FTD / ALS Associated With the GGGGCC Repeat Expansion in C 9 ORF 72 (2012) (5)
Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy (2021) (5)
An MRI‐Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease (2016) (5)
FDG-PET evaluation of pleural abnormalities (1994) (5)
Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: Preclinical to clinical correlations (2008) (5)
Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia (2020) (5)
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model (2021) (5)
Cerebral imaging of decompression injury patients with 18-F-2-fluoro-2-deoxyglucose positron emission tomography. (1994) (5)
Positive positron emission tomography (PET) pre-autologous stem cell transplant (ASCT) in non-Hodgkin lymphoma (NHL) does not preclude successful outcome (2006) (5)
Applications of positron emission tomography imaging, intraoperative ultrasonography, magnetic resonance imaging, and angiography in the evaluation of renal masses (2004) (5)
The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia (2020) (5)
Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. (2020) (5)
Patterns of neurodegeneration in dementia reflect a global functional state space (2020) (4)
Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease (2022) (4)
Clinical evaluation of a prototype time-of-flight PET/CT system (2009) (4)
Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal (2021) (4)
Cerebrospinal fluid dynamics and discordant amyloid biomarkers (2021) (4)
Ex Vivo Cell Therapy by Ectopic Hepatocyte Transplantation Treats the Porcine Tyrosinemia Model of Acute Liver Failure (2020) (4)
β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia (2021) (4)
Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies (2022) (4)
Medial temporal atrophy in posterior cortical atrophy and its relationship to the cingulate island sign (2022) (4)
11C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen ≤0.1 ng/ml (2020) (4)
Radioguided surgical advancements for head and neck oncology. (2000) (4)
PiB PET/CT identification of meningiomas is not due to presence of amyloid-beta within tumors (2012) (4)
Age , Sex , and APOE ε 4 Effects onMemory , Brain Structure , and β-Amyloid Across the Adult Life Span (2015) (4)
A Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Cetuximab and Radiation Therapy in Advanced Head and Neck Malignancies (2012) (4)
Uptake of AV-1451 in meningiomas (2017) (4)
White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition (2022) (4)
Non-right handed primary progressive apraxia of speech (2018) (4)
Patterns of Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: Unique Identification of Sites of Recurrence Impacting Clinical Management (2016) (4)
Multiple sclerosis is associated with lower amyloid but normal tau burden on PET (2020) (3)
PET and PET/CT Imaging in Head and Neck Cancer (2006) (3)
FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0 (2020) (3)
LONGITUDINAL CHANGES IN BRAIN MRI AND NEUROPSYCHOLOGICAL MEASURES IN ASYMPTOMATIC AND SYMPTOMATIC FAMILIAL FRONTOTEMPORAL LOBAR DEGENERATION WITH MUTATIONS IN MAPT (2014) (3)
Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk (2022) (3)
Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin (2021) (3)
Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes (2021) (3)
Squamous Cell Carcinoma: Restaging and Response to Therapy. (2007) (3)
Normal uptake of F-18 FDG in the sublingual gland. (2006) (3)
Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer’s disease: a series of clinical cases (2022) (3)
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease (2022) (3)
Cerebral Microbleeds (2021) (3)
Amyloid- b deposition and regional grey matter atrophy rates in dementia with Lewy bodies (2016) (3)
MP09-16 CONTEMPORARY MAPPING OF POST-PROSTATECTOMY PROSTATE CANCER RELAPSE WITH C-11 CHOLINE PET AND MULTIPARAMETRIC MRI (2016) (3)
VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR (2019) (3)
Amyloid- and tau-PET imaging in a familial prion kindred (2018) (3)
P1-288: Automated ROI analysis of 11C Pittsburgh compound B images using structural magnetic resonance imaging atlases (2008) (3)
PET and Radiotherapy (2004) (3)
Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy (2021) (3)
In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease. (2019) (3)
Sleep quality and cortical amyloid-β deposition in postmenopausal women of the Kronos early estrogen prevention study. (2021) (3)
A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment (2021) (3)
Abstract 104: Topographic White Matter Hyperintensity Patterns Associated With Alzheimer Pathologies (2019) (3)
Comparison of 11C-Pittsburgh Compound B and 18F-Flutemetamol White Matter Binding in PET (2021) (3)
Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study (2021) (3)
The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer (2022) (3)
Statins and Brain Health: Alzheimer’s and Cerebrovascular Disease Biomarkers in Older Adults (2018) (2)
ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA (2018) (2)
Age-specific population frequencies of amyloidosis and neurodegeneration among cognitively normal people age 50-89 years: a cross-sectional study (2015) (2)
Positron emission tomography scanning in lung cancer. (2003) (2)
Clinical Evaluation of Two Modeling Programs in Assessing Neurodegenerative Disease in 18F-FDG PET Imaging. (2016) (2)
Quantitative comparison of three novel 18F-labeled ligands for PET imaging of brain amyloid-{beta} plaques in Alzheimer's disease (2008) (2)
AMYLOID-B, NEUROPSYCHIATRIC SYMPTOMS AND THE RISK OF INCIDENT MILD COGNITIVE IMPAIRMENT: THE MAYO CLINIC STUDY OF AGING (2016) (2)
Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. (2021) (2)
CSF phosphorylated tau as an indicator of subsequent tau accumulation (2022) (2)
Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11 C-Choline Positron Emission (2015) (2)
Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications (2018) (2)
Recurrence Patterns of Oligometastatic Disease Detected Using C-11 Choline Positron Emission Tomography/Computed Tomography in Patients With a Rising Prostate-Specific Antigen Level Following Postprostatectomy Radiation Therapy (2016) (2)
Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. (2021) (2)
Brain amyloid, cortical thickness, and changes in activities of daily living (2020) (2)
Radiation induced oxidation of [18F]fluorothia fatty acids under cGMP manufacturing conditions. (2019) (2)
The Overlap Index as a Means of Evaluating Early Tau PET Signal Reliability (2022) (2)
THAL AMYLOID PHASE: CLINICOPATHOLOGIC AND PIB-PET IMPLICATIONS OF AD PATHOPHYSIOLOGY (2014) (2)
Author Correction: Performance of plasma phosphorylated tau 181 and 217 in the community. (2022) (2)
The value of PET/CT to assess clinically negative necks (2012) (2)
Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere–Predominant Logopenic Progressive Aphasia (2021) (2)
Peripheral Markers of Neurovascular Unit Integrity and Amyloid-β in the Brains of Menopausal Women (2018) (2)
The neural basis of visual naming errors in Alzheimer's disease: A positron emission tomography study (1995) (2)
Neurodegeneration of the visual word form area in a patient with word form alexia (2021) (2)
Evaluation of an iterative reconstruction algorithm that models the detector response of the PET scanner (2012) (2)
NETWORK-BASED TAU DEPOSITION PATTERNS ARE RELATED TO FUNCTIONAL NETWORK FAILURE LARGELY VIA BETA-AMYLOID ACROSS THE ALZHEIMER’S SPECTRUM (2016) (2)
Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia (2020) (2)
1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults (2022) (2)
NETWORK-BASED TAU DEPOSITION PATTERNS ARE RELATED TO FUNCTIONAL NETWORK FAILURE LARGELY VIA BETA-AMYLOID ACROSS THE ALZHEIMER’S SPECTRUM (2016) (2)
DETERMINING THE UTILITY OF PMOD IMAGE QUANTIFICATION SOFTWARE FOR PROCESSING [11C]PIB AND [18F]FLUTEMETAMOL IMAGES IN A PET-ONLY PIPELINE TO GENERATE SUVR FOR QUANTIFICATION ON THE CENTILOID SCALE (2017) (2)
ACCELERATED FAILURE TIME AS A MODEL FOR AMYLOID AND TAU ACCUMULATION (2018) (1)
Fluorodeoxyglucose positron emission tomography in the evaluation of tumors of the nasopharynx, paranasal sinuses, and nasal cavity (2004) (1)
WE‐G‐214‐02: Utility of 18F‐FDOPA PET for Radiotherapy Target Delineation in Glioma Patients (2011) (1)
Temperature and anticoagulant dependence of F-18 FDG labeling of leukocytes (2000) (1)
Blood‐brain barrier insulin resistance decreases insulin uptake and increases amyloid beta uptake in Alzheimer's disease brain (2020) (1)
Deciphering the clinico‐radiological heterogeneity of dysexecutive Alzheimer’s disease using unsupervised machine learning techniques (2022) (1)
PHYSICAL EXERCISE AND THE OUTCOME OF INCIDENT DEMENTIA: THE MAYO CLINIC STUDY OF AGING (2014) (1)
Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer’s disease (2022) (1)
Genome‐wide association study of tau‐PET: Association of variant near NTNG2 with resistance to tau deposition (2020) (1)
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies (2023) (1)
REGIONAL BETA-AMYLOID PET COMPARISON ACROSS ATYPICAL AND TYPICAL VARIANTS OF ALZHEIMER’S DISEASE (2016) (1)
2039 IMPACT OF 11C-CHOLINE PET/CT SCAN ON DETECTION OF RECURRENT PROSTATE CANCER IN MEN WITH BIOCHEMICAL RECURRENCE FOLLOWING FAILED INITIAL TREATMENT (2012) (1)
Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. (2019) (1)
Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome (2017) (1)
Asymmetric caudate hypometabolism in the absence of frontal involvement on FDG‐PET in patients with semantic dementia and behavioral symptoms (2020) (1)
COMPARISON OF [18F]FLUTAMETAMOL AND [11C]PIB IN NORMAL YOUNG, NORMAL ELDERLY, AND ALZHEIMER'S DISEASE SUBJECTS (2016) (1)
Comparison of FASTlab and TRACERLAB FX synthesizers (2007) (1)
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels (2022) (1)
18F FDG PET/CT imaging of primary extradrenal paragangliomas (2006) (1)
PRACTICE EFFECTS AND LONGITUDINAL COGNITIVE CHANGE AS A FUNCTION OF AMYLOID AND NEURODEGENERATIVE IMAGING BIOMARKERS IN COGNITIVELY NORMAL INDIVIDUALS (2014) (1)
Regional white matter hyperintensities in posterior cortical atrophy and logopenic progressive aphasia (2022) (1)
Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration (2022) (1)
Primary Progressive Apraxia of Speech (PAS): A Distinct Neurodegenerative Syndrome (P07.167) (2012) (1)
AV-1451 TAU-PET BINDING IN TYPICAL AND ATYPICAL SYNDROMIC VARIANTS OF ALZHEIMER’S DISEASE (2016) (1)
0273 BASELINE EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH AN INCREASE IN BRAIN METABOLISM IN NON-DEMENTED ELDERLY: A LONGITUDINAL FDG-PET STUDY (2017) (1)
IMPLICATIONS OF RECURRENCE SITES IDENTIFICATION FOLLOWING SALVAGE TREATMENTS FOR PROSTATE CANCER USING C‐11 CHOLINE PET AND MULTIPARAMETRIC MRI: MP77‐04 (2017) (1)
THE INFLUENCE OF BETA-AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH (2018) (1)
Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. (2022) (1)
TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease. (2022) (1)
Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation (2020) (1)
Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity (2022) (1)
Design, Synthesis, and Preliminary Evaluation of [68Ga]Ga-NOTA-Insulin as a PET Probe in an Alzheimer’s Disease Mouse Model (2022) (1)
Plenary Session IV: Best AbstractsPIV-02 SALVAGE LYMPH NODE DISSECTION FOR PROSTATE CANCER NODAL RECURRENCE DETECTED BY 11C-CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (2014) (1)
18 F-FDG PET of Patients with Hu¨rthle Cell Carcinoma (2003) (1)
Quantitative characterization of brain β-amyloid using a joint PiB/FDG PET image histogram (2014) (1)
EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OVER TIME IN PIB-PET (2017) (1)
Clinicopathological associations of hemispheric dominance in primary progressive apraxia of speech (2023) (1)
IC-P3-216: Automated ROI analysis of 11C Pittsburgh Compound B images using structural magnetic resonance imaging atlases (2008) (1)
Effect of APOE and family history of dementia on Alzheimer’s imaging biomarkers in cognitively normal individuals (2013) (1)
Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Gliomas for Neurosurgical Planning and Radiotherapy Target Delineation: Preliminary Results of a Prospective Pilot Study (2011) (1)
Progressive dysexecutive syndrome due to Alzheimer’s disease: A description of 55 cases and comparisons to other clinical AD phenotypes (2020) (1)
Performance measurements of a PET/CT system with prototype SiPM detectors (2015) (1)
Radiology of the Esophagus (2019) (1)
PET Imaging of Dementia: Update 2022. (2022) (1)
Posterior cortical atrophy: Primary occipital variant (2022) (1)
Performance measurements of a whole body PET/CT system with an alternate detector configuration (2011) (1)
In-vitro binding assessment of soluble and insoluble tau protein variants with [18F]-AV1451 and [18F]-MK6240 (2022) (1)
Positron emission tomography in early detection of relapse in high-risk melanoma patients: A retrospective review (2009) (1)
Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline (2023) (1)
EFFECTS OF USING A NOVEL LONGITUDINAL PROCESSING PIPELINE FOR MEASURING CHANGE OVER TIME IN PIB-PET (2017) (1)
AMYLOID BETA EFFECTS ON INSULIN PERMEABILITY FROM PLASMA TO BRAIN MEASURED BY I-125 INSULIN SPECT IN APP/PS1 MICE (2018) (1)
Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy (2021) (1)
Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning (2022) (1)
SEX AND APOE EFFECTS ON MEMORY PERFORMANCE, NEURODEGENERATION, AND B-AMYLOID ACROSS THE ADULT LIFESPAN (2014) (1)
Dynamic Aphasia as a Variant of Frontotemporal Dementia (2021) (1)
Ectopic hepatocyte transplantation cures the pig model of tyrosinemia (2019) (1)
NEUROPATHOLOGIC FEATURES OF AV1451 TAU PET AUTORADIOGRAPHY IN DEMENTIA (2016) (1)
RTHP-02. IMPACT OF 18F-DOPA PET ON RADIOTHERAPY TARGET VOLUMES FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS; PRELIMINARY RESULTS OF A PHASE II DOSE-ESCALATION TRIAL (2018) (1)
Oncologic PET/CT interpretation and reporting approaches (2014) (1)
Dementia with Lewy Bodies: Pathological Basis of the Cingulate Island Sign (P6.332) (2014) (1)
Association of neighborhood socioeconomic disadvantage and cognitive impairment (2022) (1)
Atypical Alzheimer’s disease phenotypes with normal or borderline PET biomarker profiles (2022) (1)
LONGITUDINAL MRI AND NEUROPSYCHOLOGICAL CHANGES IN SYMPTOMATIC FRONTOTEMPORAL LOBAR DEGENERATION SUBJECTS WITH MUTATIONS IN MAPT, PGRN, AND C9ORF72 (2014) (1)
PREVALENCE OF CLINICALLY VERSUS BIOLOGICALLY DEFINED ALZHEIMER’S SPECTRUM ENTITIES USING THE NATIONAL INSTITUTE ON AGING – ALZHEIMER’S ASSOCIATION RESEARCH FRAMEWORK (2019) (1)
The relationship of primary age-related tauopathy (PART) to snap: Controversy or parallel? (2015) (1)
First-in-human PET imaging of 63Zn-zinc citrate in healthy elderly subjects and patients with Alzheimer's disease (2016) (1)
Face recognition from research brain PET: An unexpected PET problem (2022) (1)
SLEEP QUALITY AND BETA-AMYLOID DEPOSITION IN RECENTLY MENOPAUSAL WOMEN PARTICIPATING IN THE KRONOS EARLY ESTROGEN PREVENTION STUDY (KEEPS) (2019) (1)
FDG-PET of the Brain and Neuropsychiatric Symptoms in Normal Cognitive Aging: The Mayo Clinic Study of Aging (S41.006) (2015) (1)
Multimodality imaging differentiates dementia with lewy bodies from Alzheimer's disease (2011) (1)
Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. (2022) (1)
Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma. (2015) (1)
Identification of noninvasive screening variables for the prediction of amyloid accumulation in a population-based study of cognitively normal elderly individuals (2012) (1)
VASCULAR CONTRIBUTIONS TO ALZHEIMER'S DISEASE: A SYSTEMS PHYSIOLOGY PERSPECTIVE (2018) (1)
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes (2021) (1)
Relationship of APOE, age, amyloid and clinical phenotype in Alzheimer disease (2021) (1)
Identification of non-invasive screening variables for the prediction of amyloid accumulation in a population-based study of cognitively normal elderly individuals (2012) (1)
Adapting a PET Imaging Agent for Correlative Microscopy of Meningiomas and Other Intracranial Tumors (2012) (1)
NIA-AA MCI criteria applied to the Mayo Clinic Study of Aging (2012) (1)
EANM / EANO / RANO practice guidelines / SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ F-18 ] FDG (2019) (0)
STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS (2018) (0)
Cross-sectional Associations of β-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies (2022) (0)
NIA‐AA AD framework stage 2: Performance in the community (2020) (0)
White matter health in the context of Alzheimer’s disease pathophysiology (2022) (0)
Rates of PIB accumulation do plateau (2012) (0)
MICoE Outreach Report (2008) (0)
PET-CT of Thyroid Cancer (2011) (0)
O1-04-01 Quantitative evaluation of PIB PET and FDG PET in early cognitive impairment (2007) (0)
PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDG-PET IN DEMENTIA WITH LEWY BODIES (2017) (0)
Unique brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy (2022) (0)
Effects of beta-amyloid load on task-free fMRI abnormalities in dementia with Lewy bodies (2012) (0)
AV-1451 TAU-PET IN CLINICAL VARIANTS OF PROGRESSIVE SUPRANUCLEAR PALSY (2016) (0)
Regional patterns of 11C-PiB uptake and cortical atrophy distinguishes dementia with Lewy bodies from Alzheimer's disease (2010) (0)
Sex differences in brain atrophy in dementia with Lewy bodies (2023) (0)
Clinical evaluation of sequentially acquired 2D and 3D whole-body PET/CT scans (2007) (0)
Dynamic aphasia with emerging agrammatism, anomia, and aberrant frontal behaviors in a case of atypical parkinsonism (2022) (0)
AV-1451 TAU-PET IN CLINICAL VARIANTS OF PROGRESSIVE SUPRANUCLEAR PALSY (2016) (0)
Structural and Functional Imaging in Parkinsonian Syndromes 1 (2014) (0)
REGIONAL BETA-AMYLOID PET COMPARISON ACROSS ATYPICAL AND TYPICAL VARIANTS OF ALZHEIMER’S DISEASE (2016) (0)
STRESS COPING ABILITY ASSOCIATED WITH TAU IN PRECLINICAL ALZHEIMER’S DISEASE (2019) (0)
FDG-PET in Pathologically Confirmed 4R-Tauopathy Variants (P5.251) (2014) (0)
EFFECTS OFAMYLOID PATHOLOGYAND HIPPOCAMPAL NEURODEGENERATION ON COGNITIVE CHANGE IN COGNITIVELY NORMAL OLDER ADULTS (2018) (0)
Optimized ROI measures of FDG-PET improve characterization of early cognitive impairment and are comparable to PIB-PET (2011) (0)
Decline in Visual and Posterior Cortical Functions in Logopenic Progressive Aphasia (P5-6.001) (2023) (0)
Potential for Re‐Identifying Brain PET Research Participants using Face Recognition (2022) (0)
Effect of APOE and family history of dementia on Alzheimer's disease imaging biomarkers in cognitively normal subjects (2013) (0)
Abstract 10419: Identification of High-Risk Atherosclerotic Plaques in Patients With Moderate Carotid Artery Stenosis by Combined F-18 Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (2018) (0)
Abstract 6210: Loss of inflammation-related genes and inflammation inhibitors effectively targets ER- breast cancer cell metastasis (2022) (0)
Characterization of Frontotemporal Dementia +/- Amyotrophic Lateral Sclerosis Associated with the GGGGCC Repeat Expansion in C9ORF72 (S54.005) (2012) (0)
Clinical-Imaging-Pathologic Analysis in Seven Patients with Dementia: Correlations with Ioflupane SPECT Findings (P6.236) (2016) (0)
Altered functional connectivity networks in logopenic progressive aphasia and posterior cortical atrophy (2022) (0)
Clinical, neuropsychiatric, and ioflupane SPECT imaging findings in REM sleep behavior disorder (2015) (0)
MENTAL AND PHYSICAL ACTIVITY DURING THE 80-MINUTE UPTAKE TIME AFFECTS OFF-TARGET BINDING IN TAU PET SCANS (18F-FTP) (2019) (0)
The effect of diphenoxylate/atropine on bowel activity during F-18 FDG PET/CT scans of the abdomen and pelvis (2006) (0)
P2-185 Glucose metabolic patterns in amnestic mild cognitive impairment and Alzheimer's disease; an FDG pet study (2004) (0)
Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures (2022) (0)
PATTERN OF AV-1451 UPTAKE IN DEMENTIA WITH LEWY BODIES AND ITS ASSOCIATION WITH AMYLOID-BETA DEPOSITION (2016) (0)
PET TAU IMAGING WITH AV-1451 IN MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS RELATIVE TO ALZHEIMER’S DISEASE DEMENTIA AND CONTROLS (2016) (0)
Abstract 10133: Cerebrovascular Imaging Biomarkers, Neuropsychiatric Symptoms, and Mild Cognitive Impairment (2021) (0)
SUBJECT-LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU-PET, AMYLOID-PET, MRI AND FDG-PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER’S DISEASE (2017) (0)
Diabetes Is Associated with Global and Regional Hypometabolism among Elderly Persons: The Mayo Clinic Study of Aging (P07.137) (2013) (0)
DATSCAN FINDINGS IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER AND/OR COGNITIVE IMPAIRMENT (2014) (0)
O2‐12‐05: WITHDRAWN (2018) (0)
Long-term Results of a Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Treatment in Advanced Head and Neck and Esophageal Malignancies (2017) (0)
Effect of intellectual lifestyle and Alzheimer's disease biomarkers on rate of cognitive decline: Mayo Clinic Study of Aging (2013) (0)
Cingulate Hypoperfusion Is a Common Feature of the Familial Fronto-Temporal Dementias (P05.064) (2012) (0)
LONGITUDINAL ACCUMULATION OF β-AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION (2018) (0)
Optimizing software methods for measuring flortaucipir SUVR change over time (2021) (0)
MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV-1451 UPTAKE (2019) (0)
ANALYSIS OF IOFLUPANE-SPECT FINDINGS USING DATQUANT IN PATIENTS WITH IDIOPATHIC REM SLEEP BEHAVIOR DISORDER (2019) (0)
An autoradiographic evaluation of AV-1451 Tau PET in dementia (2016) (0)
Abstract 44: Associations of Atrial Fibrillation, Neuroimaging Measures of Cerebrovascular Disease and Alzheimer’S Disease-related Pathology, and Cognitive Impairment (2015) (0)
SUBJECT-LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU-PET, AMYLOID-PET, MRI AND FDG-PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER’S DISEASE (2017) (0)
Effect of Amyloid-Beta load on cognition is modified by the APOE status in a population-based sample of cognitively normal older adults (2011) (0)
The effects of 18F-FDG PET/CT on the management and prognosis of patients with bladder cancer (BCa) and upper urinary tract urothelial carcinoma (UTUC) (2017) (0)
ANALYSIS OF IOFLUPANE-SPECT FINDINGS USING DATQUANT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2019) (0)
11C-Choline Positron Emission Tomography-Detected Prostate Cancer Thoracic Metastases (2022) (0)
Combinations of amyloid and neurodegeneration biomarkers have a differential impact on cognition (2013) (0)
Potential utility of longitudinal 123I‐FP‐CIT SPECT imaging in predicting phenoconversion to overt synucleinopathy in isolated REM sleep behavior disorder (2021) (0)
Antemortem PiB binding correlates with postmortem amyloid density in a case with DLB on region of interest analysis (2010) (0)
Preservation of white matter integrity on DTI 3 years after early menopausal hormone therapies (2020) (0)
Production of Zn-63 via solution target and biodistribution in mice (2013) (0)
GENOME-WIDE ASSOCIATION STUDY OF CEREBRAL MICROBLEEDS AND INFARCTION IDENTIFIES CANDIDATE GENES FOR VASCULAR RISK IN DEMENTIA (2018) (0)
Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? Eur Urol 2017 (2017) (0)
O-35 Utility of FDG-PET in the diagnostic evaluation of small pulmonary nodules (2003) (0)
18Fluorodeoxyglucose Positron Emission Tomography Spinal Cord Hypermetabolism Discriminates Neoplastic from Inflammatory Myelopathy (P06.142) (2013) (0)
A new method for monitoring PET DQA results (2013) (0)
The usefulness of positron emission tomography (PET) scanning to identify early recurrent melanoma in high risk resected stage III and IV patients: A retrospective review (2007) (0)
IC-P-056 INTERACTION EFFECT OFAPOE-4 AND SUBJECTIVE SLEEP QUALITY ON CORTICALTHICKNESS IN COGNITIVELY HEALTHYADULTS (2019) (0)
0355 Neurobiological Correlates of Sleepiness in Middle Aged and Older Adults: A FDG-PET Study (2020) (0)
Acoustic analysis and neuroimaging correlates of diadochokinetic rates in mild-moderate primary progressive apraxia of speech (2023) (0)
SCIDOT-39. K16ApoE ENHANCES Aβ-ASSOCIATED 11C-PiB DEPOSITION AND PET SIGNAL IN APP/PS1 TRANSGENIC MICE (2019) (0)
Influence of amyloid and ApoE genotype on cognitive performance in a middle-aged cohort (2015) (0)
DECODING GLUCOSE METABOLISM IN ALZHEIMER’S DISEASE REVEALS MACRO-SCALE BRAIN ORGANIZATION RELATED TO DISEASE EXPRESSION (2019) (0)
A Case of Atypical Alzheimer’s Disease With Clinical Manifestation That Straddled the Boundary Between Primary Progressive Aphasia and Posterior Cortical Atrophy (2022) (0)
Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability (2015) (0)
BLOOD GENE EXPRESSION CHANGES IMPLICATED IN ALZHEIMER’S DISEASE (2016) (0)
VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER’S DISEASE (2018) (0)
Association between head trauma, amyloid, and neurodegeneration in a population-based study of cognitively normal participants and participants with mild cognitive impairment (2013) (0)
PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDG-PET IN DEMENTIA WITH LEWY BODIES (2017) (0)
IC-P-019 LONGITUDINAL ACCUMULATION OF b AMYLOID ON PET IN DEMENTIAWITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION PREDICTING RESILIENCYAGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
A NOVEL 18F-FDG PET-CT PATTERN IN IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (2017) (0)
In Response to Pohar (2008) (0)
Increased posterior default mode network connectivity co-occurs with incident amyloidosis prior to declining in dementia (2013) (0)
Positron emission tomography (2022) (0)
Clinical outcomes for stages of NIA-AA preclinical Alzheimer's disease (2012) (0)
COMPARISON OF 123I-FP-CIT SPECT THREE QUANTIFICATION METHODS: A CLINICOPATHOLOGIC ANALYSIS IN 23 PATIENTS (2019) (0)
THE RELATIONSHIP OF ELEVATED MEDIAL TEMPORAL LOBE AND DIFFUSE BRAIN TAU-PET SIGNAL IN CLINICALLY NORMAL PARTICIPANTS (2017) (0)
11C-choline PET-guided salvage intensity modulated radiotherapy with simultaneous integrated boost for isolated pelvic and para-aortic prostate cancer nodal recurrences: Minimal adverse effects (2017) (0)
ENHANCED BRAIN UPTAKE OF C11-PIB IN MOUSE MODEL OF ALZHEIMER'S DISEASE VIA A SYNTHETIC PEPTIDE CARRIER (2014) (0)
The utility of PET/CT imaging of head and neck cancer performed early after surgical resection and prior to adjuvant radiation therapy (2006) (0)
DaTscan Findings in Patients with Mild Cognitive Impairment, Alzheimer's Disease and Dementia with Lewy Bodies (IN3-1.008) (2013) (0)
4910016 Novel bacillus thuringiensis isolate (1990) (0)
LONGITUDINAL CHANGES IN BRAIN MRI AND NEUROPSYCHOMETRICS IN ASYMPTOMATIC AND SYMPTOMATIC FAMILIAL FRONTOTEMPORAL LOBAR DEGENERATION WITH MUTATIONS IN MAPT (2014) (0)
O1-04-08 PIB and MRI provide complementary information in imaging of AD and MCI (2007) (0)
Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. (2022) (0)
P1-161: 11C PiB and structural magnetic resonance imaging in mild cognitive impairment (2008) (0)
IC-P-064 ANALYSIS OF IOFLUPANE-SPECT FINDINGSUSINGDATQUANT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2019) (0)
VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR (2019) (0)
INVESTIGATION OF PITTSBURGH COMPOUND-B BINDING IN WHITE MATTER HYPERINTENSITIES (2017) (0)
2037 INITIAL STAGING FOR HIGH RISK PROSTATE CANCER: IS THERE A ROLE FOR 11C-CHOLINE PET/CT SCAN? (2012) (0)
REPURPOSING FDG-PET AS A DIAGNOSTIC TOOL FOR ALZHEIMER’S-RELATED TDP-43-PROTEINOPATHY (2019) (0)
ANALYSIS OF IOFLUPANE-SPECT FINDINGS USING DATQUANT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2019) (0)
Heterogeneity in longitudinal deterioration of white matter microstructural integrity in the population and its implications for cognitive aging (2020) (0)
FDG changes in PiB positive, cognitively normal subjects (2013) (0)
Evaluation of iterative reconstruction of CT images for attenuation correction in PET/CT (2013) (0)
Amyloid Beta Peptides Inhibit Glucose Transport at the Blood-brain Barrier by Disrupting Insulin-Akt Pathway in Alzheimer’s Disease (2022) (0)
Predicting amyloid PET and tau PET stages with plasma biomarkers (2023) (0)
Higher systolic and diastolic blood pressures are associated with loss of white matter integrity in postmenopausal women of the KEEPS Continuation Study (2021) (0)
MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE (2018) (0)
AD-Related Pathology and Gray Matter Atrophy Rates in Probable Dementia with Lewy Bodies (P6.232) (2016) (0)
Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures (2022) (0)
RADT-15. 18F-DOPA PET/CT SURVEILLANCE FOR GLIOBLASTOMA: A RADIOMIC MODEL FROM A PROSPECTIVE PHASE II CLINICAL TRIAL PREDICTING SURVIVAL IN IDH-WILDTYPE, MGMT-UNMETHYLATED PATIENTS (2022) (0)
Exploration of visual hallucinations – FDG‐PET associations in DLB and MCI‐LB with and without visual hallucinations (2022) (0)
LONG-TERM NSAID THERAPY IN OLDER ADULTS: EFFECTS ON AT(N)V IMAGING BIOMARKERS (2019) (0)
P3-427 MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIAWITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV-1451 UPTAKE (2019) (0)
Optimum differentiation of FTLD from AD achieved with cross‐sectional tau PET (2022) (0)
Latent space projection of brain FDG‐PET creates a powerful classifier for neurodegenerative diseases (2022) (0)
Biomarker Confirmed Alzheimer’s Disease Presenting as Amnestic, Aphasic, and Visual Variants: Hippocampal Volume Comparison (I12.009) (2016) (0)
Your brain scan may be a reflection of your genes. (2018) (0)
IC-P-067 Patterns of decreased glucose metabolism differ among younger and older mild cognitive impairment patients; an FDG PET study (2006) (0)
Comparison of Pittsburgh compound‐B and flutemetamol white matter binding (2021) (0)
CONTINUOUS MEASURES OF β-AMYLOIDOSIS AND CORTICAL THICKNESS IN RELATION TO COGNITIVE DECLINE IN COGNITIVELY NORMAL INDIVIDUALS: A POPULATION-BASED STUDY (2017) (0)
NEUROLOGY): NEUROPSYCHIATRIC SYMPTOMS ACROSS THE SPECTRUM OFAD O2-11-01 CROSS-SECTIONAL ASSOCIATIONS BETWEEN CSF BIOMARKERS OF AMYLOID AND TAU WITH NEUROPSYCHIATRIC SYMPTOMS: THE MAYO CLINIC STUDY OFAGING (2019) (0)
CLINICAL AND NEUROIMAGING BIOMARKERS OF ALZHEIMER'S DISEASE PRESENTING WITH PROGRESSIVE APHASIA (2014) (0)
SELF- AND INFORMANT-RATED DAILY FUNCTION IS ASSOCIATED WITH AMYLOID AND NEURODEGENERATIVE IMAGING IN COGNITIVELY NORMAL INDIVIDUALS (2014) (0)
Prominent Auditory Hallucinations in Behavioral Variant Frontotemporal Dementia Associated with a MAPT Mutation (P3.1-006) (2019) (0)
Optimizing PiB-PET change-over-time measurement by analysis of longitudinal reliability, plausibility, and separability (2015) (0)
550 Oncologic outcomes and biochemical predictors following salvage lymph node dissection for prostate cancer (2016) (0)
BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGING-ALZHEIMER’S CONTINUUM (2019) (0)
Positron Emission Tomography Scanning and Pathologic Assessment of Neoadjuvant Chemoradiotherapy for Esophageal Cancer (2008) (0)
SelectiveWorsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly PersonsWith β-Amyloidosis (2013) (0)
COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION (2018) (0)
FDG-PET and PiB-PET imaging in asymptomatic at-risk carriers of a novel octapeptide repeat insertion in PRNP (2013) (0)
PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER’S DISEASE DERIVED FROM AN FDG-PET BASED UNSUPERVISED MACHINE LEARNING ALGORITHM (2018) (0)
IC-P3-196: Clinical evaluation of 18F-labeled AV-138 for PET amyloid imaging in Alzheimer's disease (2008) (0)
A Comparison of FLT-PET and FDG-PET in the Evaluation of Response to Cetuximab and Radiation Therapy in Advanced Head and Neck Malignancies (2011) (0)
An MRI Atlas for Imaging and Pathologic Correlation Studies in Alzheimer’s Disease (S39.008) (2016) (0)
A longitudinal investigation of physical and cognitive activities and the outcome of trajectories of AD neuroimaging biomarkers: The Mayo Clinic Study of Aging (2022) (0)
11 C-Choline PET-Guided Salvage Radiation Therapy for Isolated Pelvic and Para-aortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Low Rates of Adverse Effects (2017) (0)
Utility of Positron Emission Tomography in Evaluation of Carcinoid Tumors Presenting as Solitary Pulmonary Nodule (2003) (0)
Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy. (2023) (0)
P-368 Utility of FDG-PET in the evaluation of small cell lung carcinoma (2005) (0)
Clinical evaluation of AV-138 for PET amyloid imaging (2008) (0)
Baseline and Longitudinal Ioflupane SPECT Findings in DLB and MCI‐LB (2022) (0)
Unique brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy (2022) (0)
Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography (2022) (0)
Administration noncovalent mediated peptide active agents through the blood brain barrier (2010) (0)
PET MEASUREMENTS OF PHF TAU BURDEN IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE AND NO COPIES OF THE APOE4 ALLELE (2018) (0)
FDG PET, Aging and APOE Genotype in Cognitively Normal Persons (S8.006) (2014) (0)
2040 DETECTION OF CONSOLIDATED DISEASE RECURRENCES OF PROSTATE CANCER BY 11C-CHOLINE PET/SCAN: RESULTS CONFIRMED BY SURGICAL RESECTION (2012) (0)
PLASMA TOTAL TAU, COGNITIVE DECLINE, AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY ON AGING (2017) (0)
Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans (2020) (0)
P1-367 COMPARISON OF IOFLUPANE-SPECT FINDINGSUSINGDATQUANT IN PATIENTS WITHALZHEIMER’S DISEASEDEMENTIA AND DEMENTIAWITH LEWY BODIES (2019) (0)
Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech (2022) (0)
HETEROGENEOUS PRESENTATIONS IN POSTERIOR CORTICAL ATROPHY (2018) (0)
Longitudinal outcomes and profiles of distinct biomarker clusters based on vascular disease, neurodegeneration, and amyloid deposition (2015) (0)
PET TAU IMAGING WITH AV-1451 IN MICROTUBULE-ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS RELATIVE TO ALZHEIMER’S DISEASE DEMENTIA AND CONTROLS (2016) (0)
Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values (2018) (0)
Evidence of reduced neuronal plasticity to education in ApoE-ɛ4 carriers (2015) (0)
Serial Evaluation of PiB Accumulation in White Matter (2016) (0)
O-068 Sensitivity of FDG-PET in the diagnostic evaluation of small pulmonary nodules (2005) (0)
Semantic Variant Primary Progressive Aphasia Associated with the C9orf72 Hexanucleotide Expansion – A Longitudinal Case Report (P13-6.004) (2023) (0)
Mo1230 Characteristics and Significance of Incidental Gastrointestinal Tract Lesions Found on (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging (2013) (0)
Association between head trauma, amyloid and neurodegeneration in a population-based study of cognitively normal and mild cognitive impairment participants (2013) (0)
Impaired Cognitive Function in Alcohol Use Disorder Cohort in Aged Population (2023) (0)
PREDICTING AMYLOID DEPOSITION IN PROGRESSIVE APHASIA AND APRAXIA OF SPEECH USING CLINICAL AND MRI DATA (2016) (0)
CLINICAL AND NEUROIMAGING BIOMARKERS OF ALZHEIMER'S DISEASE PRESENTING WITH PROGRESSIVE APHASIA (2014) (0)
RELATIONSHIP OF C-REACTIVE PROTEIN, URIC ACID, LIPID PROFILE WITH TYPE 2 DIABETES MELLITUS IN TRINIDAD (2015) (0)
Utility of ioflupane‐SPECT with multimodal imaging in dementia with Lewy bodies (2020) (0)
Latent space projection of brain FDG‐PET creates a powerful classifier for neurodegenerative diseases (2022) (0)
Focality of Incidental Gastrointestinal Tract Uptake on (18)F-FDG PET/CT Imaging Is Highly Sensitive for Primary Gastrointestinal Neoplasia: 2095 (2013) (0)
Parkin-mediated mitophagy is negatively regulated by FOXO3A, which inhibits Plk3-mediated mitochondrial ROS generation in STZ diabetic stress-treated pancreatic β cells (2023) (0)
A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma (2009) (0)
Exploring alternative splicing and gene expression of load candidate genes in blood (2015) (0)
Clinical Evaluation of Respiratory Gated Magnetic Resonance-Based Attenuation Correction of PET/MR (2019) (0)
CogState computerized testing is associated with amyloid and FDG-PET: Implications for secondary preventive trials (2013) (0)
Multimodality imaging differentiates dementia with lewy bodies from Alzheimer's disease (2011) (0)
Hypometabolism in PiB-positive, population-based, cognitively normal subjects with and without APOE-ε4 (2013) (0)
Witnessed Apneas During Sleep are Associated with Elevated Tau-PET Signal in the Entorhinal Cortex in Cognitively Unimpaired Elderly (P3.6-021) (2019) (0)
Treatment with 17β-estradiol in postmenopausal women is associated with lower PiB-PET retention (2015) (0)
The many faces of globular glial tauopathy: A clinical and imaging study (2022) (0)
O2-13-06 PITTSBURGH COMPOUND-B BINDING IN WHITE MATTER HYPERINTENSITIES IS ASSOCIATEDWITH LOSS OF WHITE MATTER INTEGRITY ON DTI (2018) (0)
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis (2022) (0)
DISCOVERING SOURCES OF VARIABILITY IN AMYLOID DEPOSITION USING DATA-DRIVEN ANALYSES (2019) (0)
Longitudinal beta-amyloid PET in atypical Alzheimer’s disease and frontotemporal lobar degeneration (2020) (0)
DATSCAN FINDINGS IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER AND/OR COGNITIVE IMPAIRMENT (2014) (0)
CROSS-SECTIONAL ASSOCIATIONS BETWEEN CSF BIOMARKERS OF AMYLOID AND TAU WITH NEUROPSYCHIATRIC SYMPTOMS: THE MAYO CLINIC STUDY OF AGING (2019) (0)
CHARACTERIZATION OF THE CLINICAL AND NEUROIMAGING FEATURES OF PATIENTS WITH DEMENTIA WITH LEWY BODIES ASSOCIATED WITH VARIANTS IN GLUCOCEREBROSIDASE (GBA) (2017) (0)
Phase II Evaluation Of Stereotactic Ablative Radiotherapy (SABR) in 11C-Choline PET/CT (Cho-PET)-Identified Oligometastatic Castration-Resistant Prostate Cancer (CRPC) (2020) (0)
MENTAL AND PHYSICAL ACTIVITY DURING THE 80-MINUTE UPTAKE TIME AFFECTS OFF-TARGET BINDING IN TAU PET SCANS (18F-FTP) (2019) (0)
REGION-LEVEL RELATIONSHIPS BETWEEN TAU, AMYLOID, HYPOMETABOLISM AND ATROPHY IN ATYPICAL ALZHEIMER’S DISEASE (2018) (0)
Head and Neck Cancer Imaging (2021) (0)
A quantitative analysis of PET in patients with diagnosed argyrophilic grain disease (2013) (0)
Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder (2023) (0)
AMYLOID PET, TAU PET, AND MRI MEASUREMENTS IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE, AND NO COPIES OF THE APOE4 ALLELE (2019) (0)
LONGITUDINAL ACCUMULATION OF β-AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION (2018) (0)
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and morphological imaging in recurrent urothelial carcinomas: A retrospective, multi-center study (2017) (0)
Posterior Cortical Atrophy: Primary Occipital Variant (2022) (0)
APATHY AND REDUCED STRIATAL UPTAKE IN DEMENTIA WITH LEWY BODIES (2014) (0)
Biomarker correlates in the ADNI Alzheimer's disease dementia population suggesting dementia unlikely due to Alzheimer's (2012) (0)
INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING (2018) (0)
Role of FDG-PET/CT in managing patients with primary CNS lymphoma (2006) (0)
CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING (2017) (0)
Characteristics of REM Sleep Behavior Disorder Affect the Risk of Developing an Overt Synucleinopathy (P6-13.005) (2023) (0)
IC-P-144 PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER’S DISEASE DERIVED FROM AN FDG-PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM (2018) (0)
Multicenter Trial of Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685 (2019) (0)
Use of exploratory INDs in evaluation of 18F-labeled PET amyloid plaque imaging agents (2008) (0)
Mapping prostate cancer (CaP) recurrence after prostatectomy with c-11 choline PET/CT and 3T pelvic MRI in the contemporary era. (2016) (0)
BIOMARKERS FOR CAPTURING AMYLOID-INDEPENDENT EFFECTS OF VASCULAR HEALTH ON COGNITIVE DECLINE (2019) (0)
A retinal deep phenotypingTM platform to predict the cerebral amyloid PET status in older adults (2021) (0)
REGIONAL TAU-PET UPTAKE PATTERNS AND THEIR ASSOCIATION WITH BRAAK STAGING, COGNITION, AND ONSET OF AD-DEMENTIA (2016) (0)
THE INFLUENCE OF AGE ON REGIONAL [18F]AV-1451 PET, PITTSBURGH COMPOUND B PET AND MRI ATROPHY IN ATYPICAL ALZHEIMER’S DISEASE (2018) (0)
Amyloid PET in the Lewy Body disease continuum (2022) (0)
Sex differences in grey matter networks in dementia with Lewy bodies (2023) (0)
Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia (2021) (0)
Effects of Aβ load on task-free fMRI abnormalities in dementia with Lewy bodies (2012) (0)
Posterior Cingulate Involvement Does Not Argue Against LATE (2022) (0)
Distinct brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy (2022) (0)
STRESS: BETTER COPING ASSOCIATED WITH LOWER TAU IN PRECLINICAL ALZHEIMER'S DISEASE (2019) (0)
TAR DNA‐binding protein 43 (TDP‐43) contributes to the mismatch between medial temporal volumes and flortaucipir uptake in elderly patients with Alzheimer’s disease neuropathologic changes (2022) (0)
Effect of lifestyle activities on Alzheimer's biomarkers and cognition (2012) (0)
FP-CIT SPECT and neuropathologic findings amongpatients with neurodegenerative syndromes from the Mayo Alzheimer’s Disease (2019) (0)
Non-covalent peptide-FEED of active agents across the blood brain barrier (2010) (0)
Deconvolution of plasma pharmacokinetics from dynamic heart imaging data obtained by SPECT/CT imaging (2022) (0)
DIAGNOSTIC UTILITY OF [18F]AV-1451 PET, FDG-PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA (2018) (0)
Plasma membrane phospholipid labeling to estimate tumor burden and kinetics (2008) (0)
Effect of APOE on rate of change in PIB retention across the cognitive continuum (2011) (0)
MULTIPLE SCLEROSIS MASQUERADING AS ALZHEIMER'S TYPE DEMENTIA: CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS (2014) (0)
RESILIENCE FACTORS FOR AMYLOID DEPOSITION AND NEURODEGENERATION ARE DIFFERENT (2016) (0)
C11-choline PET scan for prostate cancer patients with biochemical recurrence (2011) (0)
Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT). (2012) (0)
Treatment with 17β-estradiol in postmenopausal women is associated with lower PiB-PET retention (2015) (0)
Corrigendum to “Prosodic and phonetic subtypes of primary progressive apraxia of speech” [Brain Lang. 184 (2018) 54–65] (2020) (0)
Altered functional connectivity networks in logopenic progressive aphasia and posterior cortical atrophy (2022) (0)
Exploiting blood transcriptome for gene and pathway identification in Alzheimer's disease (2015) (0)
TAU PET IMAGING CORRELATES WITH NEUROPATHOLOGY (2019) (0)
Temporal Cortical Thickness and Cognitive Associations among Typical and Atypical Phenotypes of Alzheimer’s Disease (2022) (0)
COMPARISON OF IOFLUPANE-SPECT FINDINGS USING DATQUANT IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA AND DEMENTIA WITH LEWY BODIES (2019) (0)
APOE AND EDUCATION: EFFECTS ON REGIONAL TAU AND FDG METABOLISM IN OLDER ADULTS (2019) (0)
CLINICAL FEATURES, CSF BIOMARKERS, MOLECULAR IMAGING, AND PATHOLOGY IN DYSEXECUTIVE ALZHEIMER’S DISEASE (2018) (0)
MULTIMODAL IMAGING APPROACH TO UNDERSTAND THE IMPACT OF VASCULAR HEALTH ON BRAIN DIFFUSION, PERFUSION, METABOLISM, AND STRUCTURE (2017) (0)
Progress Report Dominion Experimental Substation, Fort Vermilion, Alberta, 1939-1948. (1950) (0)
Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual (2021) (0)
Quantitative characterization of brain β-amyloid in 718 normal subjects using a joint PiB/FDG PET image histogram (2016) (0)
CTNI-28. VOLUMETRIC AND DOSIMETRIC PATTERNS OF FAILURE ANALYSIS OF A PHASE II CLINICAL TRIAL OF 18F-DOPA-PET DIRECTED DOSE ESCALATED RADIOTHERAPY FOR GLIOBLASTOMA (2021) (0)
18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy—Results from Multicenter ACRIN 6685 Clinical Trial (2022) (0)
ELIGIBILITY FOR AN EXERCISE STUDY IN ASYMPTOMATIC PRE-ALZHEIMER'S DISEASE (2014) (0)
Antiphospholipid syndrome mimicking posterior cortical atrophy and the “railroad track” sign on brain fluorodeoxyglucose-positron emission tomography (2023) (0)
White Matter Degeneration Pathways Associated with Tau Deposition in Alzheimer’s Disease (2022) (0)
3D registration of micro PET-CT for measurable correlates of dyspeptic symptoms in mice (2009) (0)
NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer. (2021) (0)
Neurochemical levels measured by 1H MR spectroscopy are associated with amyloid‐β and tau deposition in cognitively unimpaired older adults (2021) (0)
IC-P3-205: Development of novel 18F Aβ amyloid imaging agents (2008) (0)
ENTORHINAL CORTEX TAU PET, CORTICAL THICKNESS AND MEMORY PERFORMANCE IN COGNITIVELY UNIMPAIRED PERSONS (2018) (0)
11C-PiB PET and hippocampal volumes are complementary in distinguishing dementia with Lewy bodies and Alzheimer's disease (2009) (0)
Primary progressive apraxia of speech: Clinico-pathological associations of left-right hemispheric dominance (S8.008) (2023) (0)
Dramatic improvement with donepezil in a case of dementia with Lewy bodies (2013) (0)
P2-198 Patterns of decreased glucose metabolism differ among younger and older mild cognitive impairment patients; an FDG PET study (2006) (0)
tau-PET signal elevation in selective basal forebrain nuclei is associated with excessive daytime sleepiness in cognitively unimpaired middle aged and older adults (2019) (0)
Circulating Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in 11C Choline-identified Oligometastatic Castration-Refractory Prostate Cancer Treated with Stereotactic Ablative Radiotherapy (2021) (0)
COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION (2018) (0)
Biomarker correlates in the ADNI Alzheimer's dementia population suggesting dementia unlikely due to Alzheimer's disease (2012) (0)
CD33, MEF2C, and SORL1 are associated with variability in macroscale functional brain architecture in AD (2020) (0)
IC-P-082 TAU AND ALPHA-SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIATHERAPEUTIC’S PM-PBB3 BINDING-SITE FOCUSED COMPOUND COLLECTION (2018) (0)
Disrupted brain dynamics across the Alzheimer’s disease spectrum is related to tau accumulation (2020) (0)
Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology (2021) (0)
LONGITUDINAL BEHAVIOR OF BETA-AMYLOID IN NEURODEGENERATIVE DEMENTIAS (2019) (0)
Effect of APOE on rate of change in PIB retention across the cognitive continuum (2011) (0)
FDG-PET and PiB-PET imaging in asymptomatic at-risk carriers of a novel octapeptide repeat insertion in PRNP (2013) (0)
An examination of atypical primary progressive aphasia variants (2021) (0)
Potential for Re‐Identifying Brain PET Research Participants using Face Recognition (2022) (0)
Prospective Trial Utilizing 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET-Guided Biopsy and Resection of Recurrent Glioma (2017) (0)
COMPARISON OF 123I-FP-CIT SPECT THREE QUANTIFICATION METHODS: A CLINICOPATHOLOGIC ANALYSIS IN 23 PATIENTS (2019) (0)
ANALYSIS OF IOFLUPANE-SPECT FINDINGS USING DATQUANT IN PATIENTS WITH IDIOPATHIC REM SLEEP BEHAVIOR DISORDER (2019) (0)
Progression of Cerebral Atrophy and Hypometabolism in the presence of β-amyloidosis in mild cognitive impairment (S41.007) (2015) (0)
PITTSBURGH COMPOUND-B BINDING IN WHITE MATTER HYPERINTENSITIES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY ON DTI (2018) (0)
Baseline CSF phosphorylated tau as an indicator of subsequent tau accumulation on tau PET (2021) (0)
COMPARISON BETWEEN THE DIAGNOSTIC ACCURACIES OF 18F‐FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET)/COMPUTED TOMOGRAPHY (CT) AND MORPHOLOGICAL IMAGING IN RECURRENT UROTHELIAL CARCINOMAS: A RETROSPECTIVE, MULTI‐CENTER STUDY: PD11‐01 (2017) (0)
Optimized ROI measures of FDG—PET improve characterization of early cognitive impairment and are comparable to PIB—PET (2011) (0)
ENHANCED BRAIN-UPTAKE OF C11-PIB IN A MOUSE MODEL OF ALZHEIMER'S DISEASE VIA A SYNTHETIC PEPTIDE CARRIER (2014) (0)
Serial FDG and PiB PET in cognitive impairment (2009) (0)
Development of a robust MRI metric for longitudinal studies in Alzheimer's disease (2012) (0)
Olfactory Dysfunction and Neuroimaging Biomarkers Among Cognitively Normal Individuals (S35.006) (2016) (0)
Functional connectivity is associated with tau spreading in dementia with Lewy bodies (2020) (0)
Quantitative Analysis of FDG PET Improves Diagnositc Interpretation in Detection of Mild Cognitive Impairment and Alzheimer's Disease (2010) (0)
Performance evaluation of a high resolution PET/CT system for brain imaging (2012) (0)
MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV-1451 UPTAKE (2019) (0)
Translational Molecular Imaging (2005) (0)
VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER’S DISEASE (2018) (0)
Beyond risk of amyloid and tau: Genetics of resilience using GWAS, imaging biomarkers, and longitudinal cognitive data (2021) (0)
The Overlap Index: A new means for early detection of serial tau PET signal change (2021) (0)
White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition (2022) (0)
AV1451 PET IMAGING IN THE SPECTRUM OF ALZHEIMER’S DISEASE FROM CLINICALLY NORMAL TO DEMENTIA (2016) (0)
INVESTIGATION OF PITTSBURGH COMPOUND-B BINDING IN WHITE MATTER HYPERINTENSITIES (2017) (0)
Utility of semiquantitative analysis of FDG brain PET/CT for differentiation between patients with normal cognition, MCI, and AD (2013) (0)
ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor (2023) (0)
APATHY AND REDUCED STRIATAL UPTAKE IN DEMENTIA WITH LEWY BODIES (2014) (0)
Toronto: HAI Amyloid Imaging Conference Abstracts This concludes a six-part series of the HAI Amyloid Imaging Conference. See also (2010) (0)
Amyloid-β, Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Prospective Cohort Study (S35.003) (2016) (0)
Amyloid independent pathways have an impact on longitudinal tau deposition (2022) (0)
PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER’S DISEASE DERIVED FROM AN FDG-PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM (2018) (0)
Hypometabolism in PiB-positive, population-based, cognitively normal subjects with and without APOE-ɛ4 (2013) (0)
Alzheimer disease Short-term clinical outcomes for stages of NIAAA preclinical (2012) (0)
Comparison of [18F]F‐CNBI and [18F]F‐CNPIFE as Positron Emission Tomography Probes for Noninvasive Imaging of Glycogen Synthase Kinase‐3 in Normal Mice (2022) (0)
P1-087: The role of Positron Emission Tomography (PET) in the evaluation of Paraneoplastic Neurologic Syndrome (PNS) (2007) (0)
Association of Performance on the Financial Capacity Instrument–Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults (2022) (0)
Oral Sessions: O4-06: Dementia with Lewy Bodies P261 O4-05-06 RED BLOOD CELL FATTYACID PROFILES ARE SIGNIFICANTLYALTERED IN MILD COGNITIVE IMPAIRMENTAND ALZHEIMER’S DISEASE CASES AND POTENTIALLY DIAGNOSTICALLY RELEVANT (2014) (0)
TAU DISSEMINATION PATTERNS IN THE BRAIN BEFORE AND AFTER DEMENTIA (2018) (0)
PATHOLOGIC ASSOCIATIONS OF FDG PET IN LEWY BODY DISEASE (2019) (0)
Better intellectual lifestyle to keep cognitive impairment away (2015) (0)
IC-P1-031: 11C PiB and structural magnetic resonance imaging in Mild Cognitive Impairment (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Val J. Lowe?

Val J. Lowe is affiliated with the following schools:

Karlsruhe Institute of Technology

Val J. Lowe's Academic­Influence.com Rankings

Val J. Lowe's Degrees

Why Is Val J. Lowe Influential?

Val J. Lowe's Published Works

Published Works

What Schools Are Affiliated With Val J. Lowe?

Val J. Lowe's AcademicInfluence.com Rankings